Biopharmaceutical Contract Development and Manufacturing (CDMO) Market is expected to reach USD 32.7 billion by 2031

Biopharmaceutical Contract Development and Manufacturing (CDMO) Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the biopharmaceutical contract development and manufacturing (CDMO) market will expand from USD 19.2 billion in 2026 to USD 32.7 billion in 2031 at a CAGR of 11.2% during the forecast period.

The market is changing fast with the introduction of complex biologics, biosimilars and advanced therapy medicinal products (ATMPs). To cut capital expenditure, tap into specialized capabilities and gain flexibility in operations, pharmaceutical and biotechnology companies are increasingly turning to CDMOs to outsource development and manufacturing. Further, innovations such as innovations in bioprocessing, single-use technologies and continuous manufacturing are adding to the strength of the market growth.

Request a free sample copy or view the report summary: Biopharmaceutical contract development and manufacturing (CDMO) Market Report

Biopharmaceutical Contract Development and Manufacturing (CDMO) Market Report Highlights

• By Service type, drug development services and process development & optimization are witnessing strong growth due to the increasing need for efficient biologics development and scalable production processes. Clinical and commercial manufacturing remain core revenue-generating segments, while fill-finish and packaging & labeling services are gaining traction with the growing demand for end-to-end solutions. Analytical and quality testing services are also expanding due to stringent regulatory requirements and the need for product validation.

• In terms of Molecule type, biologics are dominating the market, as they are extensively used for treating chronic and complex diseases. As patents expire and there is a need for the cost effective alternatives, biosimilars are experiencing tremendous growth. The fastest growing segment is the advanced therapy medicinal products (ATMP) such as cell and gene therapies, where the number of approvals and investments in personalized medicine are growing.

• By End-user, pharmaceutical companies account for a significant market share due to large-scale outsourcing strategies. Biotechnology firms and emerging biotech startups are increasingly relying on CDMOs for specialized capabilities and infrastructure. Research institutes and government organizations are also contributing to market demand, particularly in early-stage development and innovation.

• By Geography, North America accounts for the highest market share, which can be attributed to the presence of well-established biopharmaceutical firms, advanced manufacturing facilities, and favorable regulatory policies. Biologics research activity is strong in Europe and strong growth is expected in Asia-Pacific due to cost benefits, growing biotech ecosystems, and increased outsourcing.

Biopharmaceutical Contract Development and Manufacturing (CDMO) Market Growth Drivers and Restraints

Growth Drivers:

• Rising Outsourcing by Pharma & Biotech Companies: Companies are outsourcing their development and manufacturing processes to CDMOs to cut costs, decrease inefficiency, and focus on core business activities like R&D and commercialization.

• Growing Demand for Biologics and Advanced Therapies: As the demand for these increases, specialized manufacturing capabilities are being sought, increasing reliance on CDMOs with advanced expertise and infrastructure.

Restraints:

• Regulatory and Compliance Challenges: Biologics manufacturing and quality assurance are subject to strict regulatory requirements, which can add to the complexity of the project and extend timelines.

• Capacity Constraints and High Capital Investment: Advanced biomanufacturing facilities will need to be established and maintained, which requires a lot of investment. These capacity constraints can affect CDMOs to satisfy increasing demand.

Biopharmaceutical Contract Development and Manufacturing (CDMO) Market Key Development

• Product Launch: In October 2025, Lifecore Biomedical, Inc., a fully integrated contract development and manufacturing organization, announced that it has signed an agreement with a leading global pharmaceutical company.

Biopharmaceutical Contract Development and Manufacturing (CDMO) Market Segmentation

Knowledge Sourcing Intelligence has segmented the Biopharmaceutical contract development and manufacturing (CDMO) by service type, molecule type, end-user and geography:

Biopharmaceutical Contract Development and Manufacturing (CDMO) Market, By Service Type

• Drug Development Services

• Process Development & Optimization

• Analytical & Quality Testing Services

• Clinical Manufacturing

• Commercial Manufacturing

• Fill-Finish Services

• Packaging & Labeling Services

Biopharmaceutical Contract Development and Manufacturing (CDMO) Market, By Molecule Type

• Biologics

• Biosimilars

• Advanced Therapy Medicinal Products (ATMPs)

Biopharmaceutical Contract Development and Manufacturing (CDMO) Market, By End-User

• Pharmaceutical Companies

• Biotechnology Firms

• Emerging Biotech Startups

• Research Institutes

• Government Organizations

Biopharmaceutical Contract Development and Manufacturing (CDMO) Market, By Region

• North America

  • USA

  • Canada

  • Mexico

• South America

  • Brazil

  • Argentina

  • Others

• Europe

  • United Kingdom

  • Germany

  • France

  • Spain

  • Others

• Middle East and Africa

  • Saudi Arabia

  • UAE

  • Others

• Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Indonesia

  • Thailand

  • Others

Biopharmaceutical Contract Development and Manufacturing (CDMO) Market Key Players

• Lonza Group AG

• Catalent, Inc.

• WuXi Biologics

• Boehringer Ingelheim

• Thermo Fisher Scientific

• AGC Biologics

• Rentschler Biopharma SE

• Fujifilm Diosynth Biotechnologies

• Charles River Laboratories

• Siegfried Holding AG